CellaVision AB
STO:CEVI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (47.8), the stock would be worth kr197.77 (63% upside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 29.3 | kr121.2 |
0%
|
| 3-Year Average | 47.8 | kr197.77 |
+63%
|
| 5-Year Average | 69.5 | kr287.17 |
+137%
|
| Industry Average | 16.2 | kr66.81 |
-45%
|
| Country Average | 21.3 | kr88.1 |
-27%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
|
CellaVision AB
STO:CEVI
|
2.9B SEK | 29.3 | 18.9 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.5B USD | 65.7 | 57.3 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
157.7B USD | 29 | 24.8 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 21.3 | 35.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.9B USD | 27.4 | 22.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
85.4B USD | 29.8 | 23.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 36.8 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 41.4 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 46.1 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.4B USD | 17.5 | 24.1 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.1B USD | 17.1 | 20 |
Market Distribution
| Min | 0.6 |
| 30th Percentile | 12.2 |
| Median | 21.3 |
| 70th Percentile | 31.9 |
| Max | 19 008.8 |
Other Multiples
CellaVision AB
Glance View
CellaVision AB engages in the provision of automated microscopy systems in the field of hematology. The company is headquartered in Lund, Skane and currently employs 200 full-time employees. The company went IPO on 2007-05-28. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
